Ralf Mueller

Showing 1-5 of 5 articles

Substitution of ethanol with specially designed microspheres in a TASH procedure

Latsios G, Gerckens U, Mueller R, Grube E

February 21, 2011

Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry)

Godino C, Parodi G, Furuichi S, Latib A, Barbagallo R, Goktekin O, Cera M, Mueller R, Tamburino C, Grube E, Di Mario C, Reimers B, Chieffo A, Antoniucci D, Colombo A, Sangiorgi G

April 12, 2010

One year results of a new in situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: results of the CUSTOM-II trial

Stella P, Mueller R, Pavlakis G, De Bruyne B, Hauptmann K-E, Morice M, Chevalier B, Fajadet J, Sievert H, Grube E

August 20, 2008

Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results

Grube E, Sievert H, Hauptmann K-E, Mueller R, Gerckens U, Buellesfeld L, Ako J, Shimohama T, Costa M, Fitzgerald P

May 13, 2008

Local intra-renal fenoldopam infusion causes greater increases in renal artery flow velocity than systemic intravenous fenoldopam infusion: a pilot study

Grube E, Baim D, Burkhoff D, Mueller R, Buellesfeld L, Teirstein P

November 20, 2005

1

Latest news

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

Don’t Miss #EIJOnAir 2nd Edition!

Elective cardiac invasive procedures during the COVID-19 outbreak

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Valvular disease